Skip to main content

Table 4 Number of hypermethylated markers in recurrent lesions

From: Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence

  Sensitivity (%) Specificity (%) Accuracy (%)
(95%CI) (95%CI) (95%CI)
a) FHIT, MLH1, ATM    
≥1 61.29 (43.82-76.27) 93.61 (82.84-97.81) 80.76 (72.02-89.52)
≥2 22.58 (11.40-39.81) 100 (92.44-100) 69.23 (58.99-79.47)
≥3 6.45 (1.79-20.72) 100 (92.44-100) 62.82 (52.09-73.55)
b) FHIT, MLH1, ATM, TP73, BRCA1    
≥1 70.96 (53.41-83.90) 85.11 (72.31-92.59) 79.49 (70.53-88.45)
≥2 38.71 (23.73-56.18) 95.74 (85.75-98.83) 73.08 (63.24-82.92)
≥3 16.13 (7.09-32.63) 100 (92.44-100) 66.66 (56.21-77.13)
≥4 6.45 (1.79-20.72) 100 (92.44-100) 62.82 (52.09-73.55)
≥5 3.22 (0.57-16.19) 100 (92.44-100) 61.53 (50.74-72.34)
c) FHIT, MLH1    
≥1 58.06 (40.77-73.58) 95.74 (85.75-98.83) 80.77 (72.02-89.52)
≥2 9.68 (3.35-24.90) 100 (92.44-100) 64.10 (53.45-74.75)
  1. Sensitivity, R patients who were correctly identified by the hypermethylated profile; Specificity, NR patients who were correctly identified by the hypermethylated profile; Accuracy, R patients, correctly identified by the hypermethylated profile, and NR patients, correctly identified by the hypermethylated profile, divided by the total series; 95% CI, 95% confidence intervals.